PFE's oncology gains and obesity re-entry contrast with NVO's GLP-1 pressures in this in-depth comparison of two healthcare ...

Next-generation weight loss pills are expected to hit the market next year, and drugmakers are working on medications with ...

Amanda Bynes is feeling her new body amid her weight-loss journey. The Nickelodeon alum, 39, shared an Instagram Story of ...

The pharma giant said amycretin helped patients lose weight and reduce blood-sugar levels in pill and injection forms during ...

About valuation, the current forward P/E is 13, but that number only looks cheap because earnings are at an unsustainably ...

Pill versions of the obesity drugs now taken only as injections are on the way. We look at the science behind the pills and if they might be more affordable and accessible than the shots.

As competitive as the obesity drug market has become, Novo Nordisk's decision to slash the prices of its GLP-1 agonist drugs ...

New GLP-1 weight-loss drugs may preserve muscle, protect skin, and reduce the risk of "Ozempic face." Experts explain what ...

What are the risks of taking Ozempic? Discover potential side effects and stay informed. Learn all you need to know before ...

Eli Lilly, the maker of hugely popular weight loss drugs, has reached $1 trillion in value, becoming the first publicly ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...